- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01739530
Safety of Repaircell in Healthy Volunteers
December 3, 2012 updated by: Anterogen Co., Ltd.
Phase I Study to Evaluate Safety of Repaircell in Healthy Volunteers
Allogenic differentiated adipocytes (ANT-adip-AL) is produced by well-established techniques including cell harvesting from lipoaspirates obtained from healthy donors, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes.
This was an open-label study.
Subjects were received subcutaneous injection of ANT-adip-AL and followed for 8 weeks according to the clinical trial protocol.
Study Overview
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- male, 19 years of age or older
- volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening
- informed consent form signed
Exclusion Criteria:
- volunteers who have participated in other clinical studies related cell therapy within 30 days before this clinical trial
- volunteers who received any immune-suppressive drug, corticosteroid or cytotoxic drug within the previous 30 days
- volunteers who have tattoo or scar which disturb assessment of study at injection site
- volunteers who have Creutzfeldt Jacobs disease or related disease or family history
- volunteers who have allergy to bovine-derived materials
- volunteers who have infectious disease such as hepatitis B virus (HBV), hepatitis C virus (HCV)and HIV
- volunteers who have a symptom of septicemia or diagnosis of active Tuberculosis
- volunteers who have a clinically relevant history of abuse of alcohol or drugs
- volunteers who are considered not suitable for the study by investigator
- volunteers who have history of surgery for malignant cancer in the past 5 years
- volunteers who have congenital or acquired immunodeficiency syndrome
- volunteers who have horrible anemia or thrombopenia
- volunteers who have chronic disease such cardiovascular,renal and respirometer disease
- volunteers who were immunosuppressed by disease (ex: chronic heart failure)
- volunteers who were immunodepressed by treatment of medication
- volunteers who is being treated with blood derivatives/who is going to get a blood derivatives
- volunteers who have abnormal rage of CD4/CD8 ratio
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Repaircell
allogenic differentiated adipocyte
|
allogenic differentiated adipocyte
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse events
Time Frame: week 8
|
Evaluate the safety at week 8 whether any kind of Adverse event occurs
|
week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological response II
Time Frame: week 8
|
Infiltration of immune cells by histology based on five basic parameters: (0) No evidence of immune cell infiltration in all area of the tissue, (1) Slight immune cell infiltration visible in partial area of the tissue (barely visible), (2) Obvious immune cell infiltration visible in partial area of the tissue, (3) Slight immune cell infiltration visible in all area of the tissue, and (4) Intense immune cell infiltration visible in all areas of the tissue.
|
week 8
|
Immunological response I
Time Frame: change from baseline CD4/CD8 ratio at week 8
|
CD4 (cluster of differentiation 4)/CD8 (cluster of differentiation 8) ratio
|
change from baseline CD4/CD8 ratio at week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sa-ik Bang, MD, Samsung Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
November 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
November 15, 2012
First Submitted That Met QC Criteria
November 29, 2012
First Posted (Estimate)
December 3, 2012
Study Record Updates
Last Update Posted (Estimate)
December 4, 2012
Last Update Submitted That Met QC Criteria
December 3, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- ANT-adip-AL-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet